Truncated VZV gE Induces High-Titer Neutralizing Antibodies in Mice

被引:0
|
作者
Wu, Jiehui [1 ]
Li, Hai [2 ]
Yuan, Yanping [1 ]
Wang, Ruichen [1 ]
Shi, Tianxin [1 ]
Li, Ziyi [1 ]
Cui, Qianqian [1 ]
Fu, Shihong [1 ]
Nie, Kai [1 ]
Li, Fan [1 ]
Yin, Qikai [1 ]
Du, Jiayi [3 ]
Wang, Huanyu [1 ]
Xu, Songtao [1 ]
机构
[1] Chinese Ctr Dis Control & Prevent, Natl Inst Viral Dis Control & Prevent, Natl Key Lab Intelligent Tracking & Forecasting In, Beijing 102206, Peoples R China
[2] Chinese Ctr Dis Control & Prevent, Natl Inst Viral Dis Control & Prevent, WHO WPRO Reg Reference Measles Rubella Lab, Beijing 102206, Peoples R China
[3] Yale Sch Publ Hlth, New Haven, CT 06510 USA
关键词
varicella zoster virus; herpes zoster; glycoprotein E; vaccine; neutralizing antibody; ZOSTER; VACCINE;
D O I
10.3390/vaccines12101139
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Backgrounds: A contemporary public health challenge is the increase in the prevalence rates of herpes zoster (HZ) worldwide. Methods: In this work, the gE gene structure was analyzed using bioinformatics techniques, and three plasmids of varying lengths, tgE537, tgE200, and tgE350, were expressed in Chinese hamster ovary (CHO) cells. These proteins were used to immunize BALB/c mice with Al/CpG adjuvant; ELISPOT and FCM were used to evaluate cellular immunity; and ELISA, VZV microneutralization, and FAMA assays were performed to detect antibody titers. Results: Target protein concentrations of 1.8 mg/mL for tgE537, 0.15 mg/mL for tgE200 and 0.65 mg/mL for tgE350 were effectively produced. The ability of the three protein segments to stimulate CD4+ and CD8+ T cells, as well as to cause lymphocytes to secrete IFN-gamma and IL-4, did not significantly differ from one another. Both tgE537 and tgE350 were capable of generating VZV-specific antibodies and neutralizing antibodies, while tgE350 had the highest neutralizing antibody titer (4388). There was no equivalent humoral immune response induced by tgE200. Conclusions: The results of this investigation provide the groundwork for the creation of HZ recombinant vaccines using truncated proteins as antigens.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] A Stabilized, Monomeric, Receptor Binding Domain Elicits High-Titer Neutralizing Antibodies Against All SARS-CoV-2 Variants of Concern
    Ahmed, Shahbaz
    Khan, Mohammad Suhail
    Gayathri, Savitha
    Singh, Randhir
    Kumar, Sahil
    Patel, Unnatiben Rajeshbhai
    Malladi, Sameer Kumar
    Rajmani, Raju S.
    van Vuren, Petrus Jansen
    Riddell, Shane
    Goldie, Sarah
    Girish, Nidhi
    Reddy, Poorvi
    Upadhyaya, Aditya
    Pandey, Suman
    Siddiqui, Samreen
    Tyagi, Akansha
    Jha, Sujeet
    Pandey, Rajesh
    Khatun, Oyahida
    Narayan, Rohan
    Tripathi, Shashank
    McAuley, Alexander J.
    Singanallur, Nagendrakumar Balasubramanian
    Vasan, Seshadri S.
    Ringe, Rajesh P.
    Varadarajan, Raghavan
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [32] Immunoglobulin with High-Titer In Vitro Cross-Neutralizing Hepatitis C Virus Antibodies Passively Protects Chimpanzees from Homologous, but Not Heterologous, Challenge
    Bukh, Jens
    Engle, Ronald E.
    Faulk, Kristina
    Wang, Richard Y.
    Farci, Patrizia
    Alter, Harvey J.
    Purcell, Robert H.
    JOURNAL OF VIROLOGY, 2015, 89 (17) : 9128 - 9132
  • [33] Efficacy of early transfusion of convalescent plasma with high-titer SARS-CoV-2 neutralizing antibodies in hospitalized patients with COVID-19
    Sanz, Cristina
    Nomdedeu, Meritxell
    Pereira, Arturo
    Sauleda, Silvia
    Alonso, Rodrigo
    Bes, Marta
    Brillembourg, Helena
    Garcia-Vidal, Carolina
    Millan, Anna
    Martinez-Llonch, Nuria
    Piron, Maria
    Puerta-Alcalde, Pedro
    Puig, Lluis
    Rico, Veronica
    Soriano, Alex
    TRANSFUSION, 2022, 62 (05) : 974 - 981
  • [34] Stiff person syndrome with cerebellar disease and high-titer anti-GAD antibodies
    Gordon, C. R.
    Zivotofsky, A. Z.
    Siman-Tov, T.
    Gadoth, N.
    NEUROLOGY, 2007, 68 (14) : 1161 - 1161
  • [35] Stiff person syndrome with cerebellar disease and high-titer anti-GAD antibodies
    Rakocevic, Goran
    Raju, Raghavan
    Semino-Mora, Cristina
    Dalakas, Marinos C.
    NEUROLOGY, 2006, 67 (06) : 1068 - 1070
  • [36] Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies
    Shi, Qizhen
    Wilcox, David A.
    Fahs, Scot A.
    Weiler, Hartmut
    Wells, Clive W.
    Cooley, Brian C.
    Desai, Drashti
    Morateck, Patricia A.
    Gorski, Jack
    Montgomery, Robert R.
    JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (07): : 1974 - 1982
  • [37] Stiff person syndrome with cerebellar disease and high-titer anti-GAD antibodies
    Rakocevic, G
    Raju, R
    Semino-Mora, C
    Dalakas, MC
    NEUROLOGY, 2006, 66 (05) : A152 - A152
  • [38] High-Titer Neutralizing Antibodies against the SARS-CoV-2 Delta Variant Induced by Alhydroxyquim-II-Adjuvanted Trimeric Spike Antigens
    Counoupas, Claudio
    Pino, Paco
    Stella, Alberto O.
    Ashley, Caroline
    Lukeman, Hannah
    Bhattacharyya, Nayan D.
    Tada, Takuya
    Anchisi, Stephanie
    Metayer, Charles
    Martinis, Jacopo
    Aggarwal, Anupriya
    Dcosta, Belinda M.
    Britton, Warwick J.
    Kint, Joeri
    Wurm, Maria J.
    Landau, Nathaniel R.
    Steain, Megan
    Turville, Stuart G.
    Wurm, Florian M.
    David, Sunil A.
    Triccas, James A.
    MICROBIOLOGY SPECTRUM, 2022, 10 (01):
  • [39] HIGH-TITER ANTINUCLEAR ANTIBODIES, ANTI-SSA/RO ANTIBODIES AND ANTINUCLEAR RNP ANTIBODIES IN PATIENTS WITH IDIOPATHIC THROMBOCYTOPENIC PURPURA
    KURATA, Y
    MIYAGAWA, S
    KOSUGI, S
    KASHIWAGI, H
    HONDA, S
    MIZUTANI, H
    TOMIYAMA, Y
    KANAYAMA, Y
    MATSUZAWA, Y
    THROMBOSIS AND HAEMOSTASIS, 1994, 71 (02) : 184 - 187
  • [40] High-titer AAV disrupts cerebrovascular integrity and induces lymphocyte infiltration in adult mouse brain
    Guo, Yaowei
    Chen, Junliang
    Ji, Wenyu
    Xu, Liang
    Xie, Yu
    He, Shu
    Lai, Chuying
    Hou, Kaiyu
    Li, Zeru
    Chen, Gong
    Wu, Zheng
    MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT, 2023, 31